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(Human bone marrow mononuclear cells
BMNCs. 2M-125D ; Lonza, Basel, Switzerland
(human bone marrow-derived mesenchymal stem cells BMSCs. PT-2501; Lonza) 
Dish X
Dish Y : Iwaki, Tokyo, Japan BMNCs
1 x 108 cells/cm2 10% (Sigma-Aldrich, St. Louis, MO, 
USA) (Thermo Fisher Scientific, Waltham, MA, USA)
Thermo Fisher Scientific-inc) 37
5%CO2 2
Day 7 (2,000g, 20min)
Dish X  X ( X), Dish Y
 Y ( Y) 24Well plate (Corning, NY, USA) BMSCs (Lonza)
5×103 cells/well X, Y 37 5%CO2
4  (n=10 each)
4 
MTS
MTS CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (Promega, Madison, WI, USA) 
MCP, MCP3, , , MDC, IL-6,   IL-8, IL-10, M-CSF, MIG, I309, ENA 
78, NAP 2 Wako (Osaka, Japan)  RANTES, Eotaxin-2, GRO, uPAR, sgp130 
R&D systems (Minneapolis, MN, USA) TIMP 1  Pepro Tech inc (Rocky Hill, NJ, 
USA)
 X  Y RayBio Human Cytokine Antibody Array G Series 1000 
(RayBiotech, Peachtree Corners, GA, USA) 
 X Y Net intensity 1.5
5 
10% (Sigma-Aldrich) (Thermo Fisher 
Scientific) (Thermo Fisher Scientific)
19 Medium A
19 MIG I309 IL-8 MIP- 4 Medium B MIG I309
2 Medium C 19 MIG I309 17
Medium D
Control medium Cytokine ED50 1 10
Table 1 BMSCs 48Well 5 ×103 cells/well Control 
medium 37 5%CO2 24 24
Medium A, B, C, D
(n=6 each) 24 control medium
37 5%CO2 Incucyte zoom (Essen 




Table 1 The addition concentration of cytokines 
 Cytokine Concentration ED50 
Medium A MCP3 500ng/ml 10~100ng/ml 
MIP-1  100ng/ml 1~10ng/ml 
RANTES 300ng/ml 20~30ng/ml 
MDC 500ng/ml 10~100ng/ml 
MIP-1  200ng/ml 5~20ng/ml 
IL-6 1ng/ml 0.1ng/ml 
MCP2 500ng/ml 10~100ng/ml 
I-309 500ng/ml 10~100ng/ml 
CCL24 500ng/ml 10~100ng/ml 
GRO g/ml 0.15~0.30 g/ml 
uPAR g/ml 5~10 g/ml 
IL-8 500ng/ml 10~100ng/ml 
M-CSF 10ng/ml 1ng/ml 
NAP-2 100ng/ml 1~10ng/ml 
MIG 500ng/ml 10~100ng/ml 
IL-10 20ng/ml 2ng/ml 
sgp130 g/ml 0.5~ g/ml 
TIMP1 g/ml 0.5 g/ml 
ENA-78 100ng/ml 5~10ng/ml 
Medium B MIP-1  100ng/ml 1~10ng/ml 
I-309 500ng/ml 10~100ng/ml 
IL-8 500ng/ml 10~100ng/ml 
MIG 500ng/ml 10~100ng/ml 
Medium C I-309 500ng/ml 10~100ng/ml 
MIG 500ng/ml 10~100ng/ml 
Medium D MCP3 500ng/ml 10~100ng/ml 
MIP-1  100ng/ml 1~10ng/ml 
RANTES 300ng/ml 20~30ng/ml 
MDC 500ng/ml 10~100ng/ml 
MIP-1  200ng/ml 5~20ng/ml 
IL-6 1ng/ml 0.1ng/ml 
MCP2 500ng/ml 10~100ng/ml 
CCL24 500ng/ml 10~100ng/ml 
7 
GRO g/ml 0.15~0.30 g/ml 
uPAR g/ml 5~10 g/ml 
IL-8 500ng/ml 10~100ng/ml 
M-CSF 10ng/ml 1ng/ml 
NAP-2 100ng/ml 1~10 ng/ml 
IL-10 20ng/ml 2ng/ml 
sgp130 g/ml 0.5~ g/ml 
TIMP1 g/ml 0.5 g/ml 
ENA-78 100ng/ml 5~10ng/ml 
NOTE; MCP2: Monocyte chemoattractant protein-2, MCP3: Monocyte 
chemoattractant protein-3 acrophage inflammatory protein 1
Macrophage inflammatory protein 1 Macrophage derived chemokine, 
IL-6:  Interleukin-6,  IL-8: Interleukin-8, IL-10: Interleukin-10, M-CSF: Macrophage 
colony stimulating factor, MIG: Monokine induced by interferon- , ENA78: 
Epithelial-derived neutrophil-activating protein78, NAP2: Neutrophil Activating 
Protein 2, RANTES: Regulated on activation normal T cell expressed and secreted, 
GRO: Growth related oncogene, uPAR: Urokinase-type plasminogen activator receptor, 
sgp130: Soluble Glycoprotein 130, TIMP1: Tissue inhibitor of metalloproteinase1. 
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Identification-Kit R&D Systems) Medium C Control 
medium BMSCs 100% confluence
Medium 14 Oil red O
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BMSCs (a) Dish X Dish Y BMNCs Day 7
(×40 magnification)  (b) MTS assay BMSCs
10 
BMSCs Medium X, Medium Y 4
MTS assay  (n=10 each , *p < 0.05) 
Medium X Medium Y
Medium X Medium Y 19
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Table 2 Cytokine antibody array analysis results 
Cytokine Net intensity (Medium X) Net intensity (Medium Y) Net intensity ratio
MCP3 54141.31 619.26 88.74 
MIP-  45374.43 525.39 86.27 
RANTES 954.82 39.54 25.14 
MDC 2262.52 114.57 19.71 
MIP-  25034.14 1672.28 14.96 
IL-6 44012.18 4349.78 10.12 
MCP2 1087.69 130.60 8.35 
I-309 364.86 56.34 6.49 
CCL24 712.62 129.55 5.51 
GRO 4360.48 934.14 4.67 
uPAR 1005.71 247.30 4.05 
IL-8 1525.89 539.74 2.82 
M-CSF 215.73 89.17 2.48 
NAP-2 496.07 200.48 2.47 
MIG 678.31 358.74 1.89 
IL-10 817.19 460.72 1.77 
sgp130 442.00 229.92 1.74 
TIMP1 1321.80 825.79 1.60 
ENA-78 260.73 166.55 1.55 
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Fig 2. BMSCs Medium
 (a) BMSCs Medium A Control medium
(n=6 each , *p < 0.05) (b) MTS assay Medium
Medium 5 MTS assay (n=6 each , *p 




Fig.3 BMSCs Medium BMSCs
Control medium 24 Medium
Medium 5 (a)(b) 
Medium A Medium B Control medium
MTS assay (n=6 each , *p < 0.05)  (c) (d) Medium B Medium 
C Control medium MTS assay (n=6 each , 
*p < 0.05) (e) (f) Medium A Medium C Control medium
MTS assay (n=6 each , *p < 0.05) (g) (h) Medium A
Medium D Control medium MTS assay
(n=6 each , *p < 0.05) (i) Medium C MIG Medium I309
Medium Control medium MTS assay
(n=6 each , *p < 0.05)
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